Biagio Ricciuti
0000-0002-0651-2678
Publication & Citation Trends
Publications
0 total
29P First-line integration of local ablative therapy (LAT) with EGFR tyrosine kinase inhibitors (TKIs) in advanced EGFR+ NSCLC: A systematic review and meta-analysis
Cited by 0
Semantic Scholar
TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors.
Cited by 0
Semantic Scholar
Impact of KRAS Mutations and Co-Alterations on Outcomes in Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiation and Immunotherapy.
Cited by 0
Semantic Scholar
555P METTHRO: Multicenter international study of thrombotic events (TE) in patients with MET-mutated NSCLC
Cited by 0
Semantic Scholar
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.
Cited by 0
Semantic Scholar
MA01.04 Neoadjuvant PD-(L)1 Blockade in Combination With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer
Cited by 0
Semantic Scholar
P2.10.11 Single-Cell RNA Sequencing Identifies ALCAM and Gpnmb as Therapeutic Targets for ADC Development in Squamous Cell Carcinoma of the Lung
Cited by 0
Semantic Scholar
P1.11.17 PD-(L)1 Inhibitors Rechallenge in Patients With Advanced NSCLC Previously Treated With Immunotherapy: A Systematic Review and Meta-Analysis
Cited by 0
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(773)
Cancer Immunotherapy and Biomarkers
(382)
Lung Cancer Research Studies
(245)
Cancer Genomics and Diagnostics
(189)
RNA modifications and cancer
(125)
Affiliations
Brigham and Women's Hospital
Fujian Medical University
The University of Texas MD Anderson Cancer Center
Harvard University
Dana (United States)